Topical Corticosteroid Alternatives

Introduction to Low Potency Agents

The American Academy of Dermatology classifies triamcinolone acetonide 0.1% as a Class IV-V (medium potency) topical corticosteroid, and for patients requiring a weaker alternative, hydrocortisone 1-2.5% cream or desonide 0.05% cream are suitable options, classified as Class VI-VII (low potency) agents 1, 2

Hydrocortisone 1-2.5% is a commonly used mild potency topical corticosteroid, classified as Class VI-VII, appropriate for mild inflammatory conditions and can be applied once or twice daily with no specified time limit for use, according to the American Academy of Dermatology 2
Desonide 0.05% is another Class VI agent that is safe for facial use and sensitive areas due to thinner skin and increased percutaneous absorption in these locations, as recommended by the American Academy of Dermatology 2
Alclometasone dipropionate 0.05% is particularly suitable for sensitive areas including the face, classified as Class VI, according to the American Academy of Dermatology 2
Fluocinolone acetonide 0.01% is a Class VI option that showed 83% good or better improvement in scalp psoriasis compared to 36% with vehicle, as reported in the Journal of the American Academy of Dermatology 3

The American Academy of Dermatology recommends using low potency agents specifically for the face and neck, intertriginous areas, genitals, and pediatric patients, due to lower risk of systemic absorption and adrenal suppression 1, 2, 4
Low potency corticosteroids demonstrate efficacy rates of 41%-83% for achieving good or excellent improvement in inflammatory skin conditions, according to the American Academy of Dermatology 1

The American Academy of Dermatology notes that low potency corticosteroids have a minimal risk of skin atrophy, telangiectasia, striae, and purpura, as well as minimal risk of hypothalamic-pituitary-adrenal axis suppression 1
Trials assessing abnormal skin thinning found that only 1% of 2,266 participants developed this complication, with only 2 cases reported with mild potency corticosteroids, as reported in the American Academy of Dermatology 1

The American Academy of Dermatology recommends topical calcineurin inhibitors, such as tacrolimus 0.03%-0.1% or pimecrolimus 1%, as steroid-sparing alternatives for facial and intertriginous areas with prolonged use beyond 4 weeks 4, 5
Crisaborole ointment or ruxolitinib cream are also options for mild-to-moderate atopic dermatitis, as reported in the Journal of the American Academy of Dermatology 5